ArticleCureus2024
Overlap of Miller-Fisher Syndrome and Pharyngeal-Cervical-Brachial Variant Secondary to COVID-19 in Recurrent Guillain-Barré Syndrome: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miller-Fisher syndrome (MFS) is characterized by the three major components of ophthalmoplegia, ataxia, and areflexia. The occurrence of MFS is relatively uncommon because of its monophasic nature, while recurrent Guillain-Barré syndrome (GBS) is a well-known condition. The pharyngeal-cervical-brachial (PCB) variant is a scarce variant of GBS (3%), which presents with muscle weakness initially involving the neck, oropharynx, and upper extremities. The patient's first symptoms were tingling in all the limbs, followed by ophthalmoplegia, ataxia, and areflexia. Additional bilateral ptosis and flu-like illness were also present. The patient subsequently developed a choking sensation with pharyngeal muscle weakness, which necessitated ventilatory support. Cerebrospinal fluid (CSF) protein levels and anti-ganglioside antibodies were both negative. During the patient's hospital admission, he received intravenous immunoglobulins (IVIGs), indicating that immunomodulating medications may be useful in managing MFS. This constellation of symptoms was induced by SARS-CoV-2 infection, confirmed by a positive polymerase chain reaction (PCR) test. This case underscores the critical role of comprehensive history-taking and physical examination in diagnosing such cases, as COVID-19-induced GBS variants have frequently demonstrated repeatedly negative antibody results. We present an unusual case of a 63-year-old male with MFS induced by COVID-19, with overlapping symptoms of the PCB variant of GBS on a background of previously recurrent GBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.